603456.SS SHH
Zhejiang Jiuzhou Pharmaceutical Co., Ltd
1W: +3.4%
1M: +10.3%
3M: +15.4%
YTD: -7.0%
1Y: -7.8%
3Y: -31.9%
5Y: -58.0%
¥16.75 ($2.50)
+0.49 (+3.01%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$11.1B
+2.5% ▲
5Y CAGR: +19.0%
Total Liabilities
$2.5B
+8.6% ▲
5Y CAGR: +6.8%
Shareholders Equity
$8.5B
+0.9% ▲
5Y CAGR: +24.5%
Cash & Investments
$2.7B
-14.3% ▼
5Y CAGR: +37.2%
Total Debt
$202M
-49.5% ▼
5Y CAGR: -25.3%
Net Debt
-$2.5B
-2.7% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $325M | $1.1B | $1.1B | $3.2B | $2.7B |
| Short-Term Investments | $27M | $26M | $0 | $0 | $0 |
| Cash & ST Investments | $352M | $1.1B | $1.1B | $3.2B | $2.7B |
| Net Receivables | $691M | $850M | $767M | $998M | $1.3B |
| Inventory | $1.2B | $1.7B | $2.0B | $2.0B | $1.9B |
| Other Current Assets | $110M | $119M | $109M | $151M | $98M |
| Total Current Assets | $2.3B | $3.8B | $4.0B | $6.3B | $6.1B |
| Property, Plant & Equip. | $2.3B | $2.6B | $3.1B | $3.7B | $4.3B |
| Goodwill & Intangibles | $311M | $498M | $628M | $682M | $662M |
| Long-Term Investments | $2M | $75M | $115M | $122M | $0 |
| Other Non-Current Assets | $64M | $39M | $8M | $11M | $119M |
| Total Non-Current Assets | $2.7B | $3.3B | $3.9B | $4.5B | $5.1B |
| Total Assets | $5.0B | $7.0B | $7.9B | $10.9B | $11.1B |
| — Liabilities — | |||||
| Accounts Payable | $530M | $640M | $842M | $610M | $920M |
| Short-Term Debt | $788M | $500M | $250M | $8M | $202M |
| Deferred Revenue | $302M | $594M | $83M | $0 | $0 |
| Other Current Liabilities | $35M | $820M | $1.0B | $676M | $623M |
| Total Current Liabilities | $1.6B | $2.1B | $2.2B | $1.7B | $2.0B |
| Long-Term Debt | $140M | $201M | $84M | $389M | $194M |
| Other Non-Current Liab. | -$2M | $0 | $26M | $51M | $42M |
| Total Non-Current Liabilities | $283M | $379M | $328M | $662M | $471M |
| Total Liabilities | $1.9B | $2.5B | $2.5B | $2.3B | $2.5B |
| — Equity — | |||||
| Common Stock | $805M | $833M | $834M | $899M | $895M |
| Retained Earnings | $1.1B | $1.6B | $2.3B | $2.9B | $3.0B |
| Accumulated OCI | $212M | $229M | $215M | $0 | $0 |
| Total Stockholders Equity | $3.1B | $4.6B | $5.3B | $8.5B | $8.5B |
| Total Liabilities & Equity | $5.0B | $7.0B | $7.9B | $10.9B | $11.1B |
| — Key Metrics — | |||||
| Total Debt | $938M | $705M | $351M | $401M | $202M |
| Net Debt | $614M | -$416M | -$744M | -$2.5B | -$2.5B |
| Total Investments | $30M | $101M | $115M | $122M | $0 |